In one study, allele-specific qPCR analysis for detecting BRAF V600 E/E2/D/K/R/M (Idylla) mutations on ctDNA was used to analyze plasma samples of patients with known BRAF V600-mutant melanoma treated with dabrafenib and trametinib in a phase II trial (n = 36 patients) [110]. This evidence concerns the gene BRAF and melanoma.